Sep 2026· IEEE transactions on computational biology and bioinformatics· Vol PP, pp. 1-15· 2 citations
Medicine
TL;DR
W WeightedCPDDI is introduced, the first conformal prediction framework tailored for DDI tasks that incorporates a novel weighting mechanism to achieve user-specific coverage and enhance prediction efficiency.
Abstract
Drug-Drug Interaction (DDI) prediction is crucial for ensuring the safety and efficacy of combination drug therapies. However, most existing methods lack uncertainty estimation, limiting their reliability and practical adoption. While conformal prediction (CP) offers guaranteed coverage in classification tasks, its direct application to DDI prediction faces challenges in achieving valid marginal coverage and efficient prediction set sizes. To overcome these limitations, this work introduces WeightedCPDDI, the first conformal prediction framework tailored for DDI tasks. WeightedCPDDI incorporates a novel weighting mechanism to achieve user-specific coverage and enhance prediction efficiency. Evaluation across transductive and inductive settings demonstrates WeightedCPDDI's strong performance. In the transductive setting, it achieves target coverage with smaller or comparable prediction sets, indicating improved calibration and efficiency. In the inductive setting, WeightedCPDDI remains competitive with or better than state-of-the-art methods in both seen-unseen and unseen-unseen scenarios, with the largest efficiency gains in the challenging unseen-unseen drug-pair setting, where it reduces prediction set sizes relative to the strongest baselines while maintaining the target coverage rate. Its strong performance across various backbone models highlights its generalizability and practical reliability for DDI prediction under uncertainty.
This work addresses one of the most pervasive obstacles to applying AI in real-world drug development by addressing conformal prediction framework tailored to label shift by weighting conformal scores using marginal label probability ratios and enhancing the trustworthiness of AI-driven predictions.
Hyeonsu Lee, Juyeong Kim, Erkhembayar Jadamba et al.· 2 citations
Drug-drug interactions (DDIs) represent a critical challenge in drug development and clinical practice, as they can lead to severe adverse effects, including toxicity and reduced therapeutic efficacy. Deep learning methods have shown promise in large-scale, rapid DDI prediction; however, current approaches suffer from...
This work investigated case studies for interactions with bupropion and ritonavir with integrated gradients and identified molecular regions associated with known CYP-mediated interaction mechanisms.
Andrew Disharoon, Shifi Pasupuleti, Clark Thurston et al.· Frontiers in Drug Safety and...· 0 citations
EQTri-DTI is designed to integrate three modality-specific networks to encode 1D protein sequences, 2D molecular images, and 3D drug structures and develops a joint uncertainty quantification scheme by calculating the weight summation of evidential uncertainty and prediction entropy from the aforementioned output, enab...
Combination therapy is a common strategy in cancer treatment to improve efficacy, minimize side effects, and overcome drug resistance. However, the vast number of possible drug pairings makes experimental screening both time-consuming and costly. Drug interactions can result in synergy and antagonism, emphasizing the n...
Azar Shamloo, Jack Tuszynski, Yun Tam et al.· International Journal of Mol...· 0 citations
Predicting drug-target affinity (DTA) is essential for screening candidate compounds in early-stage drug discovery. However, most existing computational methods formulate DTA prediction as a regression task, leading to an objective mismatch with the practical need to rank and prioritize candidate compounds based on t...
Qian Huang, Yi-Fan Wu, Lin Wang et al.· Journal of Chemical Informat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.